Prestige Consumer Healthcare closes $150M LaCorium acquisition, refinances $400M debt at higher rate

Filed July 6, 2026 · Period ending June 30, 2026 · ~1 min read

Key Changes

• high

  Closed acquisition of LaCorium Health Australia for $150M cash on July 1, 2026. LaCorium generates ~$40M annual revenue with brands including Dermal Therapy and Flexitol, expected to produce ~$12M EBITDA with synergies.

  Exhibit 99.2 verify on EDGAR →
• high

  Priced $400M senior notes at 6.25% due 2034 to refinance all $400M of 5.125% notes due 2028. Refinancing extends maturity six years but increases annual interest expense by ~$4.5M.

  Exhibit 99.2 verify on EDGAR →
• medium

  Amended term loan credit agreement to permit up to $95M in additional borrowings to partially finance the LaCorium acquisition and related fees.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →